🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. TAK-085

    Takeda

    Hyperlipidemia

    approved small molecule completed

    2 trials

  2. Tinoridine HCl

    Takeda

    Pain

    approved small molecule completed

    1 trial

  3. Treatment Algorithm A

    Takeda

    Colitis, Ulcerative

    approved mab active

    1 trial

  4. Trelagliptin

    Takeda

    Type 2 Diabetes

    approved small molecule completed

    1 trial

  5. Trelagliptin

    Takeda

    Type 2 Diabetes Mellitus

    approved small molecule completed

    2 trials

  6. Vedolizumab

    Takeda

    Crohn Disease

    approved small molecule terminated

    4 trials

  7. Vedolizumab

    Takeda

    Moderately to Severely Active Crohn's Disease

    approved mab active

    1 trial

  8. Vedolizumab

    Takeda

    Crohn's Disease

    approved small molecule active

    6 trials

  9. Vedolizumab 300 mg

    Takeda

    Colitis, Ulcerative

    approved small molecule completed

    1 trial

  10. Vedolizumab IV

    Takeda

    Colitis, Ulcerative

    approved small molecule completed

    1 trial

  11. Vedolizumab Placebo

    Takeda

    Pouchitis

    approved small molecule completed

    1 trial

  12. Velaglucerase Alfa

    Takeda

    Gaucher Disease

    approved small molecule completed

    4 trials

  13. Vonoprazan

    Takeda

    Erosive Esophagitis

    approved small molecule completed

    3 trials

  14. Vonoprazan

    Takeda

    Reflux Esophagitis

    approved small molecule completed

    1 trial

  15. Vortioxetine

    Takeda

    Type2 Diabetes

    approved small molecule terminated

    1 trial

  16. Vortioxetine

    Takeda

    Depressive Disorder

    approved small molecule terminated

    1 trial

  17. Vortioxetine

    Takeda

    Healthy Volunteers

    approved small molecule completed

    1 trial

  18. Vortioxetine

    Takeda

    Schizophrenia

    approved small molecule active

    1 trial

  19. Vortioxetine

    Takeda

    Unipolar Major Depression

    approved small molecule terminated

    1 trial

  20. Vortioxetine 10 mg

    Takeda

    Age-related Cognitive Decline

    approved small molecule completed

    1 trial

  21. Vyvanse (lisdexamfetamine dimesylate)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    approved small molecule completed

    1 trial

  22. alogliptin+pioglitazone

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule terminated

    1 trial

  23. aspirin and/or clopidogrel

    Takeda

    Early Gastric Cancer

    approved small molecule active

    1 trial

  24. dexlansoprazole

    Takeda

    Laryngopharyngeal Reflux

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources